Trial Profile
A trial to examine the effects of Rituximab on T cell lymphocytes in patients with neuromyelitis optica (NMO) and multiple sclerosis (MS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2016
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Neuromyelitis optica
- Focus Pharmacodynamics
- 04 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology